Transplantation: immunogenetic and clinical aspects--part II.
The ultimate goal is not merely to find a better way of treating acute rejection; efforts are now concentrated on prophylactic immunosuppression with low-dose regimens of azathioprine and steroids. In the wings is cyclosporine, a fungal polypeptide that shows great promise in clinical trials. And on the horizon there is hope that monoclonal antibodies may hold the key to prevention.